Qingfeng Zhu

5.2k total citations
79 papers, 2.0k citations indexed

About

Qingfeng Zhu is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Qingfeng Zhu has authored 79 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 31 papers in Molecular Biology and 18 papers in Immunology. Recurrent topics in Qingfeng Zhu's work include Cancer Immunotherapy and Biomarkers (22 papers), Immunotherapy and Immune Responses (9 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Qingfeng Zhu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Immunotherapy and Immune Responses (9 papers) and Pancreatic and Hepatic Oncology Research (7 papers). Qingfeng Zhu collaborates with scholars based in United States, China and Japan. Qingfeng Zhu's co-authors include M Clarke, Robert A. Anders, John Heuser, Elizabeth M. Jaffee, Mark Yarchoan, Timothy M. Pawlik, Elana J. Fertig, Daniel A. Laheru, Ana De Jesus‐Acosta and Ludmila Danilova and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Qingfeng Zhu

75 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qingfeng Zhu United States 24 789 690 366 342 265 79 2.0k
Jiang Wang China 25 796 1.0× 658 1.0× 163 0.4× 630 1.8× 172 0.6× 97 2.4k
Michael E. Rothenberg United States 19 1.4k 1.7× 378 0.5× 294 0.8× 362 1.1× 141 0.5× 35 2.2k
Feng‐Chiao Tsai Taiwan 20 1.3k 1.6× 341 0.5× 584 1.6× 134 0.4× 213 0.8× 33 2.4k
Katherine J. Martin United States 30 1.4k 1.8× 395 0.6× 341 0.9× 235 0.7× 102 0.4× 66 2.7k
Joep Beumer Netherlands 21 1.2k 1.5× 916 1.3× 130 0.4× 299 0.9× 171 0.6× 30 2.7k
Richard C. Kurten United States 27 1.1k 1.3× 235 0.3× 457 1.2× 472 1.4× 184 0.7× 81 2.7k
Jianping Zhang China 28 3.0k 3.8× 398 0.6× 312 0.9× 365 1.1× 163 0.6× 63 3.7k
Tae Jin Kim South Korea 29 1.1k 1.4× 515 0.7× 187 0.5× 698 2.0× 169 0.6× 122 2.6k
Yeou‐Guang Tsay Taiwan 25 971 1.2× 221 0.3× 238 0.7× 147 0.4× 179 0.7× 56 1.8k

Countries citing papers authored by Qingfeng Zhu

Since Specialization
Citations

This map shows the geographic impact of Qingfeng Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingfeng Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingfeng Zhu more than expected).

Fields of papers citing papers by Qingfeng Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingfeng Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingfeng Zhu. The network helps show where Qingfeng Zhu may publish in the future.

Co-authorship network of co-authors of Qingfeng Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Qingfeng Zhu. A scholar is included among the top collaborators of Qingfeng Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingfeng Zhu. Qingfeng Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chianchiano, Peter, Jacob T. Mitchell, Ludmila Danilova, et al.. (2025). Spatial profiling of human pancreatic ductal adenocarcinoma reveals molecular alterations associated with venous invasion. Science Translational Medicine. 17(817). eady7524–eady7524.
2.
Sun, Wei‐Chih, Juan Fu, Keyu Li, et al.. (2024). Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Science Advances. 10(42). eadp0684–eadp0684. 6 indexed citations
3.
McMiller, Tracee L., Sepideh Besharati, Mark Yarchoan, et al.. (2024). Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy. Journal for ImmunoTherapy of Cancer. 12(11). e010201–e010201. 3 indexed citations
4.
Deshpande, Atul, Hanwen Wang, Haoyang Mi, et al.. (2024). Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery. Cancer Research. 84(16). 2734–2748. 13 indexed citations
5.
Chen, Shuming, Tracee L. McMiller, Abha Soni, et al.. (2024). Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade. Journal of Translational Medicine. 22(1). 241–241. 6 indexed citations
6.
7.
Feng, Yan‐Zhao, Qingfeng Zhu, Jiao Xue, Pei Chen, & Yang Yu. (2023). Shining in the dark: the big world of small peptides in plants. aBIOTECH. 4(3). 238–256. 22 indexed citations
8.
Zhu, Qingfeng, Yan‐Zhao Feng, Jiao Xue, et al.. (2023). Advances in Receptor-like Protein Kinases in Balancing Plant Growth and Stress Responses. Plants. 12(3). 427–427. 29 indexed citations
9.
10.
Zhu, Qingfeng, et al.. (2022). Long non-coding RNA UCA1 regulates MPP+-induced neuronal damage through the miR-671-5p/KPNA4 pathway in SK-N-SH cells. Metabolic Brain Disease. 38(3). 961–972. 5 indexed citations
11.
Bracamonte‐Baran, William, Nisha A. Gilotra, Taejoon Won, et al.. (2021). Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8 + T-Cell Infiltration After Heart Transplantation. Circulation Heart Failure. 14(10). 14 indexed citations
12.
Fujikura, Kohei, Danielle Hutchings, Alicia M. Braxton, et al.. (2020). Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Modern Pathology. 33(10). 2026–2034. 10 indexed citations
13.
Llosa, Nicolás J., Brandon Luber, Nicholas Siegel, et al.. (2019). Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. Cancer Immunology Research. 7(10). 1574–1579. 32 indexed citations
14.
Danilova, Ludmila, Won Jin Ho, Qingfeng Zhu, et al.. (2019). Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. Cancer Immunology Research. 7(6). 886–895. 180 indexed citations
15.
Kim, Amy K., Faiz Gani, Andrew J. Layman, et al.. (2019). Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research. 7(5). 805–812. 20 indexed citations
16.
Yarchoan, Mark, Chiung‐Yu Huang, Qingfeng Zhu, et al.. (2019). A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Medicine. 9(4). 1485–1494. 68 indexed citations
17.
Surcel, Alexandra, Eric S. Schiffhauer, Dustin Thomas, et al.. (2019). Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14. Cancer Research. 79(18). 4665–4678. 51 indexed citations
18.
Surcel, Alexandra, Win Pin Ng, Hoku West‐Foyle, et al.. (2015). Pharmacological activation of myosin II paralogs to correct cell mechanics defects. Proceedings of the National Academy of Sciences. 112(5). 1428–1433. 52 indexed citations
19.
Xu, Yang, Venugopal Chenna, Chaoxin Hu, et al.. (2011). Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor HPI-1 (NanoHHI) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma. Clinical Cancer Research. 18(5). 1291–1302. 60 indexed citations
20.
Ai, Jing, Qingjuan Tang, Yanlin Wu, et al.. (2011). The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. JNCI Journal of the National Cancer Institute. 103(22). 1696–1712. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiang Wang Breakdown of academic impact, for papers by Michael E. Rothenberg Breakdown of academic impact, for papers by Feng‐Chiao Tsai Breakdown of academic impact, for papers by Katherine J. Martin Breakdown of academic impact, for papers by Joep Beumer Breakdown of academic impact, for papers by Richard C. Kurten Breakdown of academic impact, for papers by Jianping Zhang Breakdown of academic impact, for papers by Tae Jin Kim Breakdown of academic impact, for papers by Yeou‐Guang Tsay
Rankless by CCL
2026